VANFLYTA 17.7 mg
VANFLYTA 17.7 mg is a medicine authorised by Swissmedic under authorisation number 69710. The authorisation holder is Daiichi Sankyo (Schweiz) AG. The medicinal product code is Synthetic medicines and the dispensing category is A: Supplied only against a medical or veterinary prescription that may not be dispensed repeatedly. First authorisation was granted on 31 March 2025 and the authorisation is limited until 30 March 2030. ATC code L01EX11 places the medicine in the group Antineoplastic agents.
| Authorisation number | 69710 |
|---|---|
| Name | VANFLYTA 17.7 mg |
| Full name | VANFLYTA 17.7 mg, Filmtabletten |
| Authorisation holder | Daiichi Sankyo (Schweiz) AG |
| Medicinal product code | Synthetic medicines |
| Dispensing category | A · Prescription, not repeatable |
| ATC code | L01EX11 |
| First authorisation | 31 March 2025 |
| Authorisation validity | 30 March 2030 |
| No. | Name | Dispensing category | Authorisation date |
|---|---|---|---|
| 1 | VANFLYTA 17.7 mg, Filmtabletten | A | 31 March 2025 |
| 2 | VANFLYTA 26.5 mg, Filmtabletten | A | 31 March 2025 |
Scroll the table sideways
| Pack code | Quantity | Unit | ATC | IT code | Dispensing category |
|---|---|---|---|---|---|
| 1 | 14 | Tablette(n) | L01EX11 | 07.16.1. | A |
| 2 | 28 | Tablette(n) | L01EX11 | 07.16.1. | A |
| 3 | 14 | Tablette(n) | L01EX11 | 07.16.1. | A |
| 4 | 28 | Tablette(n) | L01EX11 | 07.16.1. | A |
| 5 | 56 | Tablette(n) | L01EX11 | 07.16.1. | A |
Scroll the table sideways
Other medicines from this authorisation holder
Frequently asked questions
Is VANFLYTA 17.7 mg authorised in Switzerland?
Yes. VANFLYTA 17.7 mg is authorised by Swissmedic under authorisation number 69710, data as of 01 September 2026. The authorisation is limited until 30 March 2030.
Which dispensing category does VANFLYTA 17.7 mg have?
VANFLYTA 17.7 mg is in dispensing category A. Supplied only against a medical or veterinary prescription that may not be dispensed repeatedly.
Who is the authorisation holder of VANFLYTA 17.7 mg?
The authorisation holder is Daiichi Sankyo (Schweiz) AG. The holder carries the legal responsibility for quality, safety and product information of the medicine in Switzerland.
Sources
Swissmedic data as of 01 September 2026. No medical advice. Independent directory, not affiliated with Swissmedic or the FOPH.